113 related articles for article (PubMed ID: 10774789)
1. Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries.
Teisman AC; Buikema H; van Veldhuisen DJ; de Zeeuw D; van Gilst WH
J Cardiovasc Pharmacol; 2000 Apr; 35(4):581-5. PubMed ID: 10774789
[TBL] [Abstract][Full Text] [Related]
2. Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats.
Teisman AC; van Veldhuisen DJ; Scholtens E; Maselbas W; van Gilst WH
J Card Fail; 1997 Sep; 3(3):199-205. PubMed ID: 9330128
[TBL] [Abstract][Full Text] [Related]
3. Z1046: a new specific peripheral dopaminergic compound.
Ferlenga P; Zanzottera D; Biasini I; Marchini F; Semeraro C
Acta Physiol Hung; 1996; 84(3):283-4. PubMed ID: 9219608
[TBL] [Abstract][Full Text] [Related]
4. Effect of epinine on tension of human renal arteries.
Schwinger RH; Schulz C; Brixius K; Böhm M; Müller-Ehmsen J; Erdmann E
Naunyn Schmiedebergs Arch Pharmacol; 1996; 354(3):343-7. PubMed ID: 8878065
[TBL] [Abstract][Full Text] [Related]
5. Z1046: biochemical characterization of its dopaminergic activity.
Fantoni M; Moriggi E; Bisiani C; Masotto C; Pocchiari F; Semeraro C
Acta Physiol Hung; 1996; 84(3):279-80. PubMed ID: 9219606
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.
Daul A; Elter-Schulz M; Poller U; Jockenhövel F; Pönicke K; Boomsma F; Man in't Veld AJ; Schäfes RF; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):429-37. PubMed ID: 8532072
[TBL] [Abstract][Full Text] [Related]
7. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular actions of the dopamine receptor agonist Z1046 in swine.
Duncker DJ; van Meegen JR; Verdouw PD
Cardiovasc Drugs Ther; 1997 Sep; 11(4):537-45. PubMed ID: 9358958
[TBL] [Abstract][Full Text] [Related]
9. Effect of dopamine, ibopamine, and epinine on alpha- and beta-adrenoceptors in canine pulmonary circulation.
Shebuski RJ; Smith JM; Ruffolo R
Fundam Clin Pharmacol; 1989; 3(3):211-21. PubMed ID: 2548941
[TBL] [Abstract][Full Text] [Related]
10. Cardiac inotropic as well as coronary and pulmonary artery actions of epinine in human isolated tissues.
Schwinger RH; Böhm M; Schulz C; Schmidt U; Schmidt U; Schmid B; Dienemann H; Reichart B; Erdmann E
J Pharmacol Exp Ther; 1993 Apr; 265(1):346-57. PubMed ID: 8386240
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamine.
Nichols AJ; Shebuski RJ; Ruffolo RR
Eur J Pharmacol; 1987 Sep; 141(3):515-8. PubMed ID: 3666046
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the alpha adrenoceptor activity of dopamine, ibopamine and epinine in the pulmonary circulation of the dog.
Shebuski RJ; Fujita T; Smith JM; Ruffolo RR
J Pharmacol Exp Ther; 1987 Apr; 241(1):6-12. PubMed ID: 3033210
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
Marchetti GV
Cardiology; 1990; 77 Suppl 5():22-9. PubMed ID: 1980631
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.
Nichols AJ; Ruffolo RR
J Pharmacol Exp Ther; 1987 Aug; 242(2):455-63. PubMed ID: 3039117
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of ibopamine.
Itoh H
Am J Med; 1991 May; 90(5B):36S-42S. PubMed ID: 1675550
[TBL] [Abstract][Full Text] [Related]
17. The dopamine receptor agonist Z1046 reduces ischaemia severity in a canine model of coronary artery occlusion.
Végh A; Papp JG; Semeraro C; Fatehi-Hasanabad Z; Parratt JR
Eur J Pharmacol; 1998 Mar; 344(2-3):203-13. PubMed ID: 9600656
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the inotropic effects of dopamine and epinine in human isolated cardiac preparations.
Bravo G; Ghysel-Burton J; Jaumin P; Godfraind T
J Pharmacol Exp Ther; 1991 Apr; 257(1):439-43. PubMed ID: 1850476
[TBL] [Abstract][Full Text] [Related]
19. Coronary vascular activity of the novel inotropic pro-drug ibopamine and the de-esterified active form epinine.
Ohlstein EH; Kopia GA; Ruffolo RR
Arzneimittelforschung; 1988 Dec; 38(12):1790-2. PubMed ID: 3245851
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vasoconstriction by potassium channel opener aprikalim in human conduit arteries used as bypass grafts.
He GW; Yang CQ
Br J Clin Pharmacol; 1997 Oct; 44(4):353-9. PubMed ID: 9354310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
